Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.
